Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07221227 Clinical Landscape Report 2026
16 September 2026
NCT07221227 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07221188 Clinical Landscape Report 2026
16 September 2026
NCT07221188 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Ravulizumab-CWVZ in Myasthenia Gravis: NCT07221838 Clinical Landscape Report 2026
16 September 2026
NCT07221838 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: CTRI/2025/11/096854 Clinical Landscape Report 2026
16 September 2026
CTRI/2025/11/096854 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GNS-3545 in Idiopathic Pulmonary Fibrosis: NCT07225296 Clinical Landscape Report 2026
16 September 2026
NCT07225296 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ABBV-142 in Idiopathic Pulmonary Fibrosis: NCT07230288 Clinical Landscape Report 2026
16 September 2026
NCT07230288 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic CD19-CAR-NK Cells(Guangdong ProCapZoom Biosciences) in Myasthenia Gravis: NCT07243366 Clinical Landscape Report 2026
16 September 2026
NCT07243366 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SPK-8011 in Hemophilia A: NCT07226206 Clinical Landscape Report 2026
16 September 2026
NCT07226206 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inno8 in Hemophilia A: NCT07238816 Clinical Landscape Report 2026
16 September 2026
NCT07238816 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Resmetirom in Metabolic Dysfunction Associated Steatohepatitis: NCT07249788 Clinical Landscape Report 2026
16 September 2026
NCT07249788 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Rozanolixizumab in Myasthenia Gravis: NCT07246564 Clinical Landscape Report 2026
16 September 2026
NCT07246564 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Telitacicept in Myasthenia Gravis, Ocular: NCT07249632 Clinical Landscape Report 2026
16 September 2026
NCT07249632 clinical landscape for Myasthenia Gravis, Ocular: endpoints, sponsor, phase, geography, readouts, asset context and development white space.